AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Nyxoah's Innovative Sleep Apnea Treatment: A Clinical Study Update
ByAinvest
Friday, Jul 18, 2025 8:57 pm ET1min read
Nyxoah announced an update on their ongoing clinical study evaluating the safety and effectiveness of their Genio® System for treating obstructive sleep apnea (OSA) in patients with complete concentric collapse of the soft palate. The Genio® System is a device that stimulates the hypoglossal nerve bilaterally to maintain an open airway during sleep. The study aims to demonstrate the system's effectiveness in reducing OSA symptoms and may positively influence Nyxoah's stock performance.
Nyxoah S.A. (NYXH) recently announced an update on their ongoing clinical study evaluating the safety and effectiveness of their Genio® System for treating obstructive sleep apnea (OSA) in patients with complete concentric collapse of the soft palate. The Genio® System is a device designed to stimulate the hypoglossal nerve bilaterally to maintain an open airway during sleep.The study, titled "A Multicenter Study to Assess the Safety and Effectiveness of the Genio® Dual-sided Hypoglossal Nerve Stimulation System for the Treatment of Obstructive Sleep Apnea in Subjects With Complete Concentric Collapse of the Soft Palate," aims to evaluate the system's effectiveness in reducing OSA symptoms. The intervention being tested is the Genio® 2.1 System, which includes an implantable stimulator and external components like an activation chip and disposable patch.
The study follows an interventional design with a single-group model and no masking, focusing primarily on treatment. Participants receive the Genio® System as the sole intervention. The study began on December 28, 2022, with recruitment currently ongoing. The primary completion and estimated study completion dates have not been specified, but the last update was submitted on July 17, 2025, indicating active progress.
This clinical update could positively influence Nyxoah’s stock performance by showcasing innovation in OSA treatment, potentially increasing investor confidence. The Genio® System’s unique approach may set Nyxoah apart from competitors in the sleep apnea device market.
Further details about the study can be found on the ClinicalTrials portal.
References:
[1] https://www.tipranks.com/news/company-announcements/nyxoahs-innovative-approach-to-sleep-apnea-a-clinical-study-update
[2] https://www.globenewswire.com/news-release/2025/07/16/3116737/0/en/Obstructive-Sleep-Apnea-Clinical-Trial-Pipeline-Expands-as-12-Companies-Driving-Innovation-in-OSA-Therapeutics-DelveInsight.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet